nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”nodgo-674Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESГемофилия А: вызовы реальной клинической практикиРумянцевА. Г.

академик РАН, д.м.н., профессор, президент ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Минздрава России, президент НОДГО, главный внештатный детский специалист онколог-гематолог Минздрава России (Москва)

ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Минздрава РоссииRussian Federation20202501202174s36Copyright © Румянцев А.Г., 20212021Румянцев А.Г.Румянцев А.Г.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/674

.

ReferencesLarsson S.A. Life expectancy of Swedish hemophiliacs, 1831–1980. Br J Haematol 1985;59:593–602. doi: 10.1111/j.1365-2141.1985.tb07353.x.Larsson S.A. Life expectancy of Swedish hemophiliacs, 1831–1980. Br J Haematol 1985;59:593–602. doi: 10.1111/j.1365-2141.1985.tb07353.x.Skjefstad K., Solberg O., Glosli H., von der Lippe C., Feragen K.B. Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986–2018. Eur J Haematol 2020. doi: 10.1111/ejh.13494.Skjefstad K., Solberg O., Glosli H., von der Lippe C., Feragen K.B. Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986–2018. Eur J Haematol 2020. doi: 10.1111/ejh.13494.Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., Key N.S., Kitchen S., Llinas A., Ludlam C.A., Mahlangu J.N., Mulder K., Poon M.C., Street A., Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1–47. doi: 10.1111/j.1365-2516.2012.02909.x.Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., Key N.S., Kitchen S., Llinas A., Ludlam C.A., Mahlangu J.N., Mulder K., Poon M.C., Street A., Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1–47. doi: 10.1111/j.1365-2516.2012.02909.x.Jiménez-Yuste V., Auerswald G., Benson G., Lambert T., Morfi ni M., Remor E., Zupančić Salek S. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus 2014;12(3):314–9. doi: 10.2450/2014.0298-13.Jiménez-Yuste V., Auerswald G., Benson G., Lambert T., Morfi ni M., Remor E., Zupančić Salek S. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus 2014;12(3):314–9. doi: 10.2450/2014.0298-13.den Uijl I.E., Mauser Bunschoten E.P., Roosendaal G., Schutgens R.E.G., Biesma D.H., Grobbee D.E., Fischer K. Clinical severity of haemophilia A: does the classifi cation of the 1950s still stand? Haemophilia 2011;17(6):849–53. doi: 10.1111/j.1365-2516.2011.02539.x.den Uijl I.E., Mauser Bunschoten E.P., Roosendaal G., Schutgens R.E.G., Biesma D.H., Grobbee D.E., Fischer K. Clinical severity of haemophilia A: does the classifi cation of the 1950s still stand? Haemophilia 2011;17(6):849–53. doi: 10.1111/j.1365-2516.2011.02539.x.Инструкция по медицинскому применению препарата Иммунат. [Электронный ресурс]: https://www.vidal.ru/drugs/immunate__6089#kinetics (дата обращения 09.2020).Instructions for the medical use of the drug Immunat. [Electronic resource]: https://www.vidal.ru/drugs/immunate__6089#kinetics (appeal date 09.2020). (In Russ.).Инструкция по медицинскому применению препарата Октанат. [Электронный ресурс]: https://www.vidal.ru/drugs/octanate__23641#kinetics (дата обращения 09.2020).Instructions for the medical use of the drug Octanate. [Electronic resource]: https://www.vidal.ru/drugs/immunate__6089#kinetics (appeal date 09.2020). (In Russ.).Valke L.F.G., Bukkems L.H., Barteling W., Laros-van Gorkom B.A.P., Blijlevens N.M.A., Mathôt R.A.A., van Heerde W.L., Schols S.E.M. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation. J Thromb Haemost 2020. doi: 10.1111/jth.15106.Valke L.F.G., Bukkems L.H., Barteling W., Laros-van Gorkom B.A.P., Blijlevens N.M.A., Mathôt R.A.A., van Heerde W.L., Schols S.E.M. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation. J Thromb Haemost 2020. doi: 10.1111/jth.15106.Garcia-Martínez I., Borràs N., Martorell M., Parra R., Altisent C., Ramírez L., Álvarez-Román M.T., Nuñez R., Megias-Vericat J.E., Corrales I., Alonso S., Vidal F. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. Thromb Haemost 2020;120(10):1395–406. doi: 10.1055/s-0040-1714214.Garcia-Martínez I., Borràs N., Martorell M., Parra R., Altisent C., Ramírez L., Álvarez-Román M.T., Nuñez R., Megias-Vericat J.E., Corrales I., Alonso S., Vidal F. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. Thromb Haemost 2020;120(10):1395–406. doi: 10.1055/s-0040-1714214.FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. [Электронный ресурс]: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors (дата обращения 09.2020).FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. [Электронный ресурс]: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors (дата обращения 09.2020).Hemlibra. European Medicines Agency. [Электронный ресурс]: https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra (дата обращения 09.2020).Hemlibra. European Medicines Agency. [Электронный ресурс]: https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra (дата обращения 09.2020).Oldenburg J., Mahlangu J.N., Kim B., Schmitt C., Callaghan M.U., Young G., Santagostino E., Kruse-Jarres R., Negrier C., Kessler C., Valente N., Asikanius E., Levy G.G., Windyga J., Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017;377(9):809–18. doi: 10.1056/NEJMoa1703068.Oldenburg J., Mahlangu J.N., Kim B., Schmitt C., Callaghan M.U., Young G., Santagostino E., Kruse-Jarres R., Negrier C., Kessler C., Valente N., Asikanius E., Levy G.G., Windyga J., Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017;377(9):809–18. doi: 10.1056/NEJMoa1703068.Uchida N., Sambe T., Yoneyama K., Fukazawa N., Kawanishi T., Kobayashi S., Shima M. A fi rst-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecifi c antibody, in healthy subjects. Blood 2016;127(13):1633–41. doi: 10.1182/blood-2015-06-650226.Uchida N., Sambe T., Yoneyama K., Fukazawa N., Kawanishi T., Kobayashi S., Shima M. A fi rst-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecifi c antibody, in healthy subjects. Blood 2016;127(13):1633–41. doi: 10.1182/blood-2015-06-650226.Shima M., Hanabusa H., Taki M., Matsushita T., Sato T., Fukutake K., Fukazawa N., Yoneyama K., Yoshida H., Nogami K. Factor VIII-Mimetic Function of Humanized Bispecifi c Antibody in Hemophilia A. N Engl J Med 2016;374(21):2044–53. doi: 10.1056/NEJMoa1511769.Shima M., Hanabusa H., Taki M., Matsushita T., Sato T., Fukutake K., Fukazawa N., Yoneyama K., Yoshida H., Nogami K. Factor VIII-Mimetic Function of Humanized Bispecifi c Antibody in Hemophilia A. N Engl J Med 2016;374(21):2044–53. doi: 10.1056/NEJMoa1511769.Kitazawa T., Igawa T., Sampei Z., Muto A., Kojima T., Soeda T., Yoshihashi K., Okuyama-Nishida Y., Saito H., Tsunoda H., Suzuki T., Adachi H., Miyazaki T., Ishii S., Kamata-Sakurai M., Iida T., Harada A., Esaki K., Funaki M., Moriyama C., Tanaka E., Kikuchi Y., Wakabayashi T., Wada M., Goto M., Toyoda T., Ueyama A., Suzuki S., Haraya K., Tachibana T., Kawabe Y., Shima M., Yoshioka A., Hattori K. A bispecifi c antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012;18(10):1570–4. doi: 10.1038/nm.2942.Kitazawa T., Igawa T., Sampei Z., Muto A., Kojima T., Soeda T., Yoshihashi K., Okuyama-Nishida Y., Saito H., Tsunoda H., Suzuki T., Adachi H., Miyazaki T., Ishii S., Kamata-Sakurai M., Iida T., Harada A., Esaki K., Funaki M., Moriyama C., Tanaka E., Kikuchi Y., Wakabayashi T., Wada M., Goto M., Toyoda T., Ueyama A., Suzuki S., Haraya K., Tachibana T., Kawabe Y., Shima M., Yoshioka A., Hattori K. A bispecifi c antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012;18(10):1570–4. doi: 10.1038/nm.2942.Инструкция по медицинскому применению препарата Эмицизумаб. [Электронный ресурс]: https://www.rlsnet.ru/tn_index_id_96727.htm#farmakokinetika (дата обращения 09.2020).Instructions for the medical use of the drug Emicizumab. [Electronic resource]: https://www.rlsnet.ru/tn_index_id_96727.htm#farmakokinetika (appeal date 09.2020). (In Russ.).Schmitt C., Adamkewicz J.I., Xu J., Petry C., Catalani O., Young G., Negrier C., Callaghan M.U., Levy G.G. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thromb Haemost 2020. doi: 10.1055/s-0040-1717114.Schmitt C., Adamkewicz J.I., Xu J., Petry C., Catalani O., Young G., Negrier C., Callaghan M.U., Levy G.G. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thromb Haemost 2020. doi: 10.1055/s-0040-1717114.Mahlangu J., Oldenburg J., Paz-Priel I., Negrier C., Niggli M., Mancuso M.E., Schmitt C., Jiménez-Yuste V., Kempton C., Dhalluin C., Callaghan M.U., Bujan W., Shima M., Adamkewicz J.I., Asikanius E., Levy G.G., Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med 2018;379(9):811–22. doi: 10.1056/NEJMoa1803550.Mahlangu J., Oldenburg J., Paz-Priel I., Negrier C., Niggli M., Mancuso M.E., Schmitt C., Jiménez-Yuste V., Kempton C., Dhalluin C., Callaghan M.U., Bujan W., Shima M., Adamkewicz J.I., Asikanius E., Levy G.G., Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med 2018;379(9):811–22. doi: 10.1056/NEJMoa1803550.Oldenburg J., Mahlangu J.N., Kim B., Schmitt C., Callaghan M.U., Young G., Santagostino E., Kruse-Jarres R., Negrier C., Kessler C., Valente N., Asikanius E., Levy G.G., Windyga J., Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017;377(9):809–18. doi: 10.1056/NEJMoa1703068.Oldenburg J., Mahlangu J.N., Kim B., Schmitt C., Callaghan M.U., Young G., Santagostino E., Kruse-Jarres R., Negrier C., Kessler C., Valente N., Asikanius E., Levy G.G., Windyga J., Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017;377(9):809–18. doi: 10.1056/NEJMoa1703068.Young G., Liesner R., Chang T., Sidonio R., Oldenburg J., Jiménez-Yuste V., Mahlangu J., Kruse-Jarres R., Wang M., Uguen M., Doral M.Y., Wright L.Y., Schmitt C., Levy G.G., Shima M., Mancuso M.E. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019;134(24):2127–38. doi: 10.1182/blood.2019001869.Young G., Liesner R., Chang T., Sidonio R., Oldenburg J., Jiménez-Yuste V., Mahlangu J., Kruse-Jarres R., Wang M., Uguen M., Doral M.Y., Wright L.Y., Schmitt C., Levy G.G., Shima M., Mancuso M.E. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019;134(24):2127–38. doi: 10.1182/blood.2019001869.Pipe S.W., Shima M., Lehle M., Shapiro A., Chebon S., Fukutake K., Key N.S., Portron A., Schmitt C., Podolak-Dawidziak M., Bienz N.S., Hermans C., Campinha-Bacote A., Kiialainen A., Peerlinck K., Levy G.G., Jiménez-Yuste V. Effi cacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019;6(6):e295–305. doi: 10.1016/S2352-3026(19)30054-7.Pipe S.W., Shima M., Lehle M., Shapiro A., Chebon S., Fukutake K., Key N.S., Portron A., Schmitt C., Podolak-Dawidziak M., Bienz N.S., Hermans C., Campinha-Bacote A., Kiialainen A., Peerlinck K., Levy G.G., Jiménez-Yuste V. Effi cacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019;6(6):e295–305. doi: 10.1016/S2352-3026(19)30054-7.Srivastava A., Santagostino E., Dougall A., Kitchen S., Sutherland M., Pipe S.W., Manuel C., Mahlangu J., Ragni M.V., Windyga J., Llinás A., Goddard N.J., Mohan R., Poonnoose P.M., Feldman B.M., Zelman Lewis S., van den Berg H.M., Pierce G.F.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26 Suppl 6:1–158. doi: 10.1111/hae.14046.Srivastava A., Santagostino E., Dougall A., Kitchen S., Sutherland M., Pipe S.W., Manuel C., Mahlangu J., Ragni M.V., Windyga J., Llinás A., Goddard N.J., Mohan R., Poonnoose P.M., Feldman B.M., Zelman Lewis S., van den Berg H.M., Pierce G.F.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26 Suppl 6:1–158. doi: 10.1111/hae.14046.Collins P.W., Liesner R., Makris M., Talks K., Chowdary P., Chalmers E., Hall G., Riddell A., Percy C.L., Hay C.R., Hart D.P. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018;24:344–7. doi: 10.1111/hae.13495.Collins P.W., Liesner R., Makris M., Talks K., Chowdary P., Chalmers E., Hall G., Riddell A., Percy C.L., Hay C.R., Hart D.P. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018;24:344–7. doi: 10.1111/hae.13495.Зозуля Н.И., Кумскова М.А., Полянская Т.Ю., Свирин П.В., Мамаев А.Н., Галстян Г.М. Гемофилия А. Клинические рекомендации, 2018. С. 17.Zozulya N.I., Kumskova M.A., Polyanskaya T.Yu., Svirin P.V., Mamaev A.N., Galstyan G.M. Hemophilia A. Clinical guidelines, 2018. P. 17. (In Russ.).Jiménez-Yuste V., Santagostino E., Klamroth R., Castaman G., Shanmukhaiah C., Rangarajan S., García Chavez J., Martinez R., Kenet G., Robson S., Schmitt C., Meier O., Ozelo M. Second Interim Analysis Results from the STASEY Trial: A Single-Arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII Inhibitors [abstract]. Res Pract Thromb Haemost 2020;4 (Suppl 1).Jiménez-Yuste V., Santagostino E., Klamroth R., Castaman G., Shanmukhaiah C., Rangarajan S., García Chavez J., Martinez R., Kenet G., Robson S., Schmitt C., Meier O., Ozelo M. Second Interim Analysis Results from the STASEY Trial: A Single-Arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII Inhibitors [abstract]. Res Pract Thromb Haemost 2020;4 (Suppl 1).Castaman G., Santagostino E., Kremer Hovinga J., Schutgens R., Robson S., Meier O., Jiménez-Yuste V. Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis [abstract]. Res Pract Thromb Haemost 2020;4 (Suppl 1).Castaman G., Santagostino E., Kremer Hovinga J., Schutgens R., Robson S., Meier O., Jiménez-Yuste V. Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis [abstract]. Res Pract Thromb Haemost 2020;4 (Suppl 1).Roche - New follow-up phase III data reinforce the long-term benefi t of Roche’s Hemlibra for people with haemophilia A. [Electronic resource]: https://www.roche.com/media/releases/med-cor-2020-12-07.htm.Roche - New follow-up phase III data reinforce the long-term benefi t of Roche’s Hemlibra for people with haemophilia A. [Electronic resource]: https://www.roche.com/media/releases/med-cor-2020-12-07.htm.Wall C., Xiang H., Palmer B., Collins P., Hart D., Hall G., Chalmers E., Benson G., Evans G., Liesner R., Makris M., Harrison C., Mangles S., Maclean R., Shapiro S., Stephensen D., Sartain P., Hay C. Real World Effi cacy of Emicizumab in Haemophilia A with Inhibitors: A Report from the UK National Haemophilia Database [abstract]. Res Pract Thromb Haemost 2020;4 (Suppl 1).Wall C., Xiang H., Palmer B., Collins P., Hart D., Hall G., Chalmers E., Benson G., Evans G., Liesner R., Makris M., Harrison C., Mangles S., Maclean R., Shapiro S., Stephensen D., Sartain P., Hay C. Real World Effi cacy of Emicizumab in Haemophilia A with Inhibitors: A Report from the UK National Haemophilia Database [abstract]. Res Pract Thromb Haemost 2020;4 (Suppl 1).Rodriguez-Merchan E.C., De la Corte-Rodriguez H. Complications of hemophilia in the elbow: current management. Expert Rev Hematol 2020;13(9):991–1001. doi: 10.1080/17474086.2020.1803061.Rodriguez-Merchan E.C., De la Corte-Rodriguez H. Complications of hemophilia in the elbow: current management. Expert Rev Hematol 2020;13(9):991–1001. doi: 10.1080/17474086.2020.1803061.Отчет по НИР «Определение количества пациентов с поставленным диагнозом Гемофилия А с ингибитором и без на территории РФ». М., 2019. С. 7.Research report “Determination of the number of patients with a diagnosis of Hemophilia A with and without an inhibitor on the territory of the Russian Federation”. M., 2019. P. 7. (In Russ.).

The authors declare that there are no conflicts of interest present.